TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
monoclonal Describing cells, proteins, or molecules descended or derived from a single clone (i.e. from the same genome or genetic lineage) or made in response to a single unique compound. Monoclonal antibodies are raised against only one antigen or can only recognize one unique epitope on the same antigen. Similarly, the cells of some tissues and neoplasms may be described as monoclonal if they are all the asexual progeny of one original parent cell. Contrast polyclonal.
Per- and Polyfluoroalkyl Substances (PFAS) at the National Toxicology Program Per- and Polyfluoroalkyl Substances and Your Health at the Agency for Toxic Substances and Disease Registry Per- and Polyfluoroalkyl Substances (PFAS) at the EPA Per- and polyfluoroalkyl substances (PFASs) at the European Chemicals Agency PFAS contamination map of Europe Per- and Polyfluoroalkyl substances, National Institute for Occupational Safety and Health The Forever Pollution Project – Journalists tracking PFAS across Europe PFAS contamination in Queensland, Australia, State Library of Queensland "Contaminated: The Carpet Industry's Toxic Legacy". Frontline. Season 44. Episode 8. 3 February 2026. PBS. WGBH. Retrieved 25 February 2026.
This spider's venom shows varied action mechanisms that affect the different parts of the nervous impulse transmission chain. As mentioned above, Argiotoxins are polyamine toxins. This biomolecular group can effectively inhibit certain ligand-gated ion channels in the central nervous system of mammals and the insects' glutamic receptor (it has been characterized as an opposite of homomeric and heteromeric glutamate-activated receptor channels ). It has been seen that it can also inhibit the following receptors: AMPA, NMDA (argiotoxin has higher potency at NMDA receptors), kainate, and nicotine acetylcholine receptors. It is thought that polyamine toxins' inhibition is both use and voltage dependent. What is more, they bind within the pore of the open channels they inhibit. A lot of attention is drawn to the pharmacological uses of polyamine toxins. They are highly valuable due to their high affinity for ionotropic glutamate receptors, important drug targets for psychiatric disorders. It has not been developed yet, although it is thought that it could be a great procedure in neuroprotection and in the treatment of Alzheimer's disease. Argiotoxin could even be used as a tool for analyzing the subunit composition of AMPA receptors in native membranes.
It mandates that "the use of artificial intelligence efforts should not compromise the integrity of nuclear safeguards, whether through the functionality of weapons systems, the validation of communications from command authorities, or the principle of requiring positive human actions in execution of decisions by the President with respect to the employment of nuclear weapons." In February 2026, the Trump Administration publicly reaffirmed that nuclear weapons decisions will remain subject to human control, with a senior Pentagon official reiterating the "Department's policy that there is a human in the loop on all decisions on whether to employ nuclear weapons". In September 2025, the French Center for AI Safety (CeSIA), The Future Society and the Center for Human-Compatible AI (CHAI) published a global call for AI red lines urging governments to reach a binding international agreement prohibiting unacceptable AI uses by the end of 2026. The declaration was initially signed by 200 prominent figures including 10 Nobel Prize winners, and was announced by Maria Ressa at the United Nations General Assembly. In December 2025, President Donald Trump signed an executive order to establish a "National Policy Framework for Artificial Intelligence". The executive order discouraged state governments from regulating AI, urging Congress to pass a law pre-empting such regulations. The White House cited economic and national security concerns as reasons for the measure, while some criticized Trump for creating uncertainty for AI regulation. On July 6, 2026, Illinois Governor J.B.
Sources: en.wikipedia.org
== Role in disease == A defect in the degradation of glucocerebrosides is Gaucher's disease. The corresponding defects for galactocerebrosides are: a) Ceramide trihexoside (globotriaosylceramide) accumulation – Fabry's disease. Clinical features include acroparaesthesia (tingling, pins and needles sensation in the extremities) b) Galactocerebroside (galactosylceramidase) accumulation – Krabbe disease.
=== General features === Although the tetrahedral intermediates are usually transient intermediates, many compounds of this general structures are known. The reactions of aldehydes, ketones, and their derivatives frequently have a detectable tetrahedral intermediate, while for the reactions of derivatives of carboxylic acids this is not the case. At the oxidation level of carboxylic acid derivatives, the groups such as OR, OAr, NR2, or Cl are conjugated with the carbonyl group, which means that addition to the carbonyl group is thermodynamically less favored than addition to corresponding aldehyde or ketone. Stable tetrahedral intermediates of carboxylic acid derivatives do exist and they usually possess at least one of the following four structural features:
{\displaystyle {\begin{aligned}u_{x}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kx-{\frac {\pi }{3}}\right)\cos \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)-\cos \left(kz-{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{y}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(ky-{\frac {\pi }{3}}\right)\cos \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)-\cos \left(kx-{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{z}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kz-{\frac {\pi }{3}}\right)\cos \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)-\cos \left(ky-{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\end{aligned}}}
==== Pat Farrell's Alpha-Angle Freeze Mark ==== A specialized brand system is required to mark many animals such that each can be individually identified. Arabic numerals are difficult to brand much smaller than 4 inches (10 cm) tall. Further, conventional numbers can be altered, with a branded "3" easily turned into an "8," potentially shifting apparent ownership of the horse. It is also inconvenient to carry a dozen or more unique brands into the field if animals must be branded there.
In 2025, Newsom signed a budget that restricted new enrollment of undocumented immigrants in Medi-Cal. Newsom signed the California Senate Bill 41 (2025) but vetoed other measures to regulate pharmacy benefit managers.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.